Imiglucerase - Biologic Drug Details

Summary for imiglucerase

Tradenames:	1
High Confidence Patents:	2
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for imiglucerase
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for imiglucerase

Recent Clinical Trials for imiglucerase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
AVROBIO	Phase 2/Phase 3
Sanofi	Phase 4
ISU Abxis Co., Ltd.	Phase 1

See all imiglucerase clinical trials

Recent Litigation for imiglucerase

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Juul Labs Inc v. EZfumes	2020-07-10
MiMedx Group, Inc. v. Tissue Transplant Technology, Ltd.	2014-05-16

See all imiglucerase litigation

Pharmacology for imiglucerase

Established Pharmacologic Class	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Chemical Structure	Glucosylceramidase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for imiglucerase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for imiglucerase Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2010-08-17	Company disclosures
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2013-08-27	Company disclosures

3) Low Certainty: US Patents for imiglucerase Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2033-03-11	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2027-09-17	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2029-10-19	Patent claims search

International Patents for imiglucerase

Country	Patent Number	Estimated Expiration
European Patent Office	0401362
Germany	68926569
Japan	H03502289